Registry study on factors predicting outcomes in aneurysmal subarachnoid hemorrhage

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

PROSAH-MPC is a collaborative research project involving multiple neurosurgical centers in China that aims to identify prognostic factors and develop prediction models for complications, disability, and mortality in patients with aneurysmal subarachnoid hemorrhage (aSAH). The study utilizes a large, multi-center, prospective cohort design to gather extensive clinical and radiological data, including demographics, medical histories, and imaging features. By employing machine learning techniques, the study seeks to extract critical predictive features from imaging data, enhancing the accuracy of the developed models. This comprehensive approach aims to provide a better understanding of aSAH outcomes and improve patient management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subarachnoid hemorrhage confirmed by computed tomography (CT);
* Cerebral angiography (CTA) and digital subtraction angiography (DSA) examination confirming intracranial aneurysm rupture as the cause of the subarachnoid hemorrhage;
* Blood routine, biochemical function, blood coagulation function, and craniocerebral CT performed within 24 hours of symptom onset;
* Underwent aneurysm clipping by surgery or endovascular embolization within 72 hours after-onset.

Exclusion Criteria:

* Aneurysm rupture bleeding time exceeding 24 hours before hospital admission;
* Incomplete image data or blood test information;
* Long-term use of anticoagulant medications such as aspirin or warfarin;
* Admitted to hospital with active infectious diseases;
* long-term anticoagulant drugs such as aspirin, wave dimensions;
* Presence of other intracranial vascular malformations.

Where it's running

• The Second Affiliated Hospital of Nanchang University
  Nanchang, Jiangxi, China Recruiting

Study contacts

• Principal investigator: Qianxue Chen, Prof — Renmin Hospital of Wuhan University
• Study coordinator: Xingen Zhu, Prof
• Email: zxg2008vip@163.com
• Phone: 13803546020

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nitric Oxide Use to Predict Vasospasm in Aneurysmal Subarachnoid Hemorrhage

  This study tests whether nitric oxide consumption in CSF can predict cerebral vasospasm in patients with aneurysmal SAH.

  Recruiting at 2 sites Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT07614906

• Multi-omics program to understand complications and outcomes after aneurysmal subarachnoid hemorrhage

  This project will test if combining blood, cerebrospinal fluid, urine, imaging, and multi-omics data can find biomarkers that predict complications and outcomes in adults with aneurysmal subarachnoid hemorrhage.

  Recruiting Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT07270419

• Dome-only coiling for severe aneurysmal subarachnoid hemorrhage

  This will test a minimally invasive dome-protection coiling procedure to prevent re-bleeding in adults who have had a severe aneurysmal subarachnoid hemorrhage.

  Recruiting University of Louisville · Louisville, Kentucky · NCT07250958

• Cilostazol to help prevent delayed brain ischemia after aneurysm bleed

  This study tests whether cilostazol can reduce delayed brain ischemia and improve outcomes after aneurysmal subarachnoid hemorrhage in adults who had recent aneurysm treatment.

  Recruiting Phase 3 Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT07249853

• Transcutaneous Vagal Nerve Stimulation to help with brain vessel narrowing after aneurysm rupture

  This trial tests whether using a noninvasive nerve stimulation device can reduce cerebral vasospasm after an aneurysmal brain bleed in adults 18–65 who are undergoing standard treatment.

  Recruiting University of Alabama at Birmingham · Birmingham, Alabama · NCT07131696

• Tocilizumab-aazg to reduce stroke risk after a ruptured brain aneurysm

  This trial will try to see if a single IV dose of tocilizumab-aazg is safe and can help prevent delayed strokes in adults who have had a ruptured brain aneurysm (aneurysmal subarachnoid hemorrhage).

  Recruiting Phase 1 University of Florida · Gainesville, Florida · NCT06863480

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.